33results about How to "Lower Level Requirements" patented technology

Methods, compositions, and systems for steeping, propagation and fermentation, particularly large-scale operations for production of starch and ethanol and fermentation product streams are provided. Addition of mycotoxin mitigating enzymes or microorganisms expressing mycotoxin mitigating enzymes to steeping, propagation, and / or fermentation tanks, and / or to post-fermentation product streams, mitigates mycotoxin levels in fermentation co-products obtained from mycotoxin contaminated feedstocks.

An inducer for reprogramming a T cell into an NK-like cell and an application of the inducer. The inducer comprises any one of or a combination of at least two of a DNA methyltransferase inhibitor, a histone deacetylase inhibitor, or a histone methyltransferase EZH2 inhibitor. The inducer is used for inducing a decrease in methylation level in T cells, inhibiting histone deacetylation and histone methylation, and expressing NK cell receptors and cytokines, thereby achieving the purpose of in-vitro reprogramming of T cells into NK-like cells. The method is simple, high in efficiency, and short in cycle, and the prepared NK-like cells have obvious in-vitro killing effects, and have important significance in the field of cell immunotherapy.

A technique for appropriately protecting electrodes of a microfluidic chip is provided. A microfluidic chip (1) includes a substrate (10), electrodes (31), insulation films (33), and a fluid holding part (20). The electrodes (31) are disposed on an upper surface of the substrate (10). The insulation films (33) cover upper surfaces of the respective electrodes (31). The insulation films (33) are comprised of an oxide film obtained by oxidizing a metal contained in the electrodes (31) or a nitride film obtained by nitriding the metal contained in the electrodes (31). The fluid holding part (20) is capable of accommodating a fluid over the insulation films (33).

The invention discloses a full-automatic single-chip microbiological detection system. The system comprises a micro-fluidic chip, a cam mechanism, a pressing module for driving the cam mechanism to do reciprocating rectilinear motion, a first on-off assembly and a second on-off assembly, during working, the pressing module drives the cam mechanism, the first on-off assembly and the second on-off assembly to linearly move to approach the micro-fluidic chip, the second on-off assembly controls the micro-fluidic chip to be communicated with the atmosphere, and the cam mechanism sequentially controls the first on-off assembly to open or close a flow channel on the micro-fluidic chip. Controlling the solution to be transferred into a target chamber for a microbiological detection experiment; various solutions are quantitatively filled into the storage cavity in the micro-fluidic chip in advance, the corresponding solutions are controlled to be transferred into the target cavity for experiments in different experiment steps based on cooperation of a cam structure, the on-off puncture assembly and the like, reagent bottles and pipelines do not need to be externally connected, operation is easy and convenient, stability is good, and reliability is high.

A GLP-1 / GIP dual-targeted polypeptide, containing a first polypeptide having the following amino acid sequence : X1X2X3GT FX4SDY SX5X6X7X8 X9X10X11X12X13 X14FX15X16W LX17X18X19, wherein X1 is Y or H, X2 is A or G or S, X3 is E or Q, X4 is I or T, X5 is I or K, X6 is A or Y or L or I, X7 is M or L, X8 is D or E, X9 is K or E, X10 is I or Q or K or E or L, X11 is H or A or R, X12 is A or Q or V, X13 is K or Q or R or H, X14 is D or E or A or L, X15 is V or I, X16 is N or E or D or Q, X17 is L or I or K or V, X18 is A or E or K, X19 is Q or G; X1~X13 do not satisfy at the same time that X1 is Y, X2 is A, X3 is E, X4 is I, X5 is I, X6 is A, X7 is M, X8 is D, X9 is K, X10 is I, X11 is H, X12 is Q, X13 is Q, X14 is D, X15 is V, X16 is N, X17 is L, X18 is A, X19 is Q. The GLP-1 / GIP dual-targeted polypeptide can effectively reduce the weight and blood sugar level.

The present invention relates to a high-speed signal transmission cable, belonging to the technical field of chip testing devices. It is characterized in that it includes a cable bundle and at least one connector module, wherein the cable bundle is composed of multiple groups of coaxial cables and a tube sleeve wrapped outside the coaxial cables, the connector module includes a spring pin, a spring sleeve, a kit base and a signal conversion block, the kit base is a step-shaped component with a central protrusion and an array of through holes arranged at the protrusion, the bottom of the kit base has a depression corresponding to the central protrusion, a through hole corresponding to the position of the through hole of the kit base is opened on the signal conversion block, and the two corresponding through holes are connected to each other after being embedded in the depression of the kit base, the spring sleeve is sleeved outside the spring pin, and the tail of the spring pin passes through the through holes of the kit base and the signal conversion block and is welded to the signal line or ground line at one end of the coaxial cable. The present invention solves the problem that the signal transmission cable is susceptible to interference and single-end uncontrollable under high frequency conditions, and can significantly improve the signal transmission quality.

The present invention relates to compositions and methods of GDNF fusion polypeptides, wherein the GDNF fusion polypeptides include an Fc domain, an albumin-binding peptide, a fibronectin domain, or a human serum albumin, joined to a GDNF variant either directly or by the way of a linker. The GDNF fusion polypeptides may used to treat metabolic diseases, such as obesity and Type-1 and Type-2 diabetes, and neurological diseases, such as Amyotrophic lateral sclerosis (ALS) and Parkinson's disease.

An siRNA targeting 17β-hydroxysteroid dehydrogenase type 13 and a siRNA conjugate. Also disclosed are a pharmaceutical composition, cell or kit containing the siRNA, and a method for using the siRNA for the treatment and / or prevention of subjects suffering from HSD17B13-related disorders (such as chronic fibroinflammatory liver disease).

The invention discloses a cigarette pack three-dimensional hot stamping device, a hot stamping system and a cigarette pack three-dimensional hot stamping method, relates to the field of tobacco production, and aims to improve the production efficiency and the qualified rate of a cigarette pack hot stamping procedure. The cigarette pack three-dimensional hot stamping device comprises a positioning plate, a buffering piece, a parchment paper material layer and a resin material layer. The positioning plate comprises a hollow part; the outline shape of the buffer piece is matched with the shape of the hollow part, and the buffer piece is located in the hollow part. The vegetable parchment material layer comprises an image-text part and a drawing part, and the image-text part and the drawing part are fixedly connected or integrated; the image-text part is located in the hollow-out part, and the drawing part is located outside the hollow-out part. The overall shape of the resin material layer is matched with that of the positioning plate, and the resin material layer is fixedly connected with the positioning plate. According to the technical scheme, the position where the pressure needs to be adjusted is directly positioned, the time for repeatedly stopping the machine to adjust the pressure is shortened, hot stamping waste products caused by machine adjustment are reduced, and the hot stamping production efficiency and the yield are improved.

The present invention provides a method and apparatus for processing to improve the properties of pyrolysis oil and, as a result, the commercial value of the same. The net result is creation of an oil with a much lighter color in lieu of the black color, reducing or elimination the undesired sulfury / amine aroma and reducing the amount of PAH which is believed to be a carcinogen.

The present invention relates to Lactobacillus rhamnosus, Bifidobacterium longum, and Lactococcus lactis, which are novel lactic acid bacteria. The strains according to the present invention have high utility as a medicine or food and, in particular, can be used for preventing, treating, or relieving inflammatory diseases and neurological diseases, due to having an excellent antioxidant effect, inflammation-relieving effect, nerve-improving effect, cognition-improving effect, intestinal microbiota imbalance-improving effect, etc. In addition, the present invention can be used for regulating and enhancing immunity by increasing the activity of the immune system through immune function-improving and immunity-enhancing effects.

The present invention belongs to the field of medicine, and relates to a compound of Formula I and a pharmaceutically acceptable salt thereof for using as a MAGL inhibitor, as well as a preparation method and use thereof, and an intermediate for preparing the same.

Some embodiments comprise a pump assembly for reduced pressure wound therapy, comprising a housing, a flow pathway through the pump, one or more valves in communication with the flow pathway, a pump supported within or by the housing, and a one-way flow valve in fluid communication with the pump. The pump assembly can have a pressure sensor in communication with the flow pathway through the pump, and at least one switch or button supported by the housing, the at least one switch or button being accessible to a user and being in communication with the controller. The one-way flow valve can be configured to substantially prevent a flow of gas through the one-way flow valve in a direction of flow away from the pump. The pump assembly can have a controller supported within or by the housing, the controller being configured to control an operation of the pump. The pump has been sterilized following the assembly of the pump such that an inside and an outside of the housing, the flow pathway, the one or more valves, the pump, the controller, the battery compartment, and the at least one switch or button have been sterilized.

The utility model provides a miniaturized radio frequency comprehensive test module, relates to the field of radio frequency test, and solves the problem that a universal desk type radio frequency instrument has many limitations in an airborne CNI system comprehensive test scene. Wherein the radio frequency sub-module comprises a power detection unit and a frequency mixer, and the power detection unit and the frequency mixer both receive radio frequency signal input; the intermediate frequency acquisition and digital signal processing sub-module comprises a detection ADC, an intermediate frequency ADC, an audio ADC, an FPGA and a DSP, the detection ADC is connected with the power detection unit, the intermediate frequency ADC is connected with the mixer, and the audio ADC receives audio signal input; the detection ADC, the intermediate frequency ADC and the audio ADC are all connected with the FPGA, and the FPGA is also connected with the DSP; the radio frequency sub-module and the intermediate frequency acquisition and digital signal processing sub-module are integrally packaged in the shell; according to the utility model, a plurality of radio frequency testing functions are integrated, and the integrated radio frequency testing device has the advantages and characteristics of high integration, integration, miniaturization and integrated design.

The invention provides a method for reducing the false positive rate of leukocytes detected by a UF-5000 urine formed component analyzer, and belongs to the field of optimization of detection methods. Aiming at the problem that the false positive rate of leukocytes is high when an existing urine analyzer detects a sample with increased epithelial cells, the invention provides a solution for effectively reducing the false positive rate, and after an optimal CR (WBC)-CW-FSC-P gain value is set, the sample with an epithelial cell interference leukocyte signal is detected. Through the method, the false positive rate of leukocytes can be remarkably reduced, so that misdiagnosis of urinary tract infection caused by the false positive rate is reduced, the accuracy of a urine analyzer is improved, and especially in pregnant women, the misdiagnosis rate can be effectively reduced, the diagnosis efficiency is improved, and unnecessary antibiotic use is reduced. The method is simple to operate, and the clinical application value of the urine analyzer can be improved.

The present invention relates to methods for treating a human patient suffering from acute kidney injury.

Disclosed in the present invention are a CLY series compound, a preparation method therefor and the use thereof in the preparation of drugs. The CLY series compound is a compound with a structure of formula I, a tautomer thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof. Animal model experiments show that the CLY series compound, in a chloasma mouse model, can obviously reduce the level oftyrosinase in the skin and blood, reduce the expression of the stem cell factor (SCF) and C-Kit protein in the skin, and inhibit the chromogenesis of chloasma, can obviously promote the healing of a wound on skin and reduce the formation of scars, in a hair loss mouse model, can obviously promote the hair growth and reduce damage to hair follicles, and in a rabbit ear acne model, can obviously reduce the symptoms and reduce pore blockage and acne formation. The CLY series compound can significantly prolong the survival time of acute GVHD mice, and can reduce clinical symptoms, exhibiting a therapeutic effect on acute GVHD; in a pulmonary fibrosis mouse model, same can obviously reduce the levels ofMMP-2 and MMP-9 in the lung tissue, increase the levels of TIMP-1 and VEGF, and simultaneously increase the levels of SOD and CAT enzymes in peripheral blood; and same can also improve the arthritis symptoms ofrheumatoid arthritis mice by means of reducing the level of IL-17 in peripheral blood and increasing inflammatory indexes such as IL-10. The compound can be used alone or in ombination with other drugs, and provides a new drug choice for the treatment of the above diseases.

The invention discloses a control method and device for a tractor capable of automatically entering and exiting a stop station. The method comprises a station entering control process and a station exiting control process. In the station entering process, the poses of the aircraft and the stopping station line are obtained firstly, then the station entering path of the aircraft is determined, and the tractor is controlled to carry the aircraft to enter the station according to the station entering path. In the departure process, firstly, the posture of front wheels of the aircraft is obtained, the wheel holding path of the tractor is determined, then the tractor is controlled to be close to and hold the front wheels of the aircraft, and finally the aircraft is dragged to leave the station. According to the method, through accurate pose acquisition and path planning, automatic control over the tractor is achieved, and the efficiency and safety of aircraft traction operation are improved.

Described herein are methods for using compounds that activate pyruvate kinase.

The present invention relates to a pharmaceutical composition for treating or preventing malignant breast cancer and, more particularly, to a composition for transdifferentiation of ER-negative breast cancer to luminal breast cancer, comprising an HDAC1 / 2 inhibitor and a BCL11A inhibitor as active ingredients, and use of the composition. According to the present invention, when target genes of the present invention are inhibited, BLT is induced so that basal-like or triplet-negative breast cancer is transdifferentiated to luminal A subtype breast cancer which is responsive to anticancer therapy, that is, being curable by hormone therapy. Accordingly, an effective and novel drug treatment that has not been conventionally attempted may be provided, thereby not only increasing the survival rate of patients through targeted therapy by realizing personalized medicine, but also contributing to an improvement in the quality of life that results from unnecessary anticancer drug therapy.

Provided is a noise-cancelling headphone device that prevents deterioration of reproduction frequency characteristics in a high-frequency band while preventing reduction in the reproduction output in the low-frequency band. The proposed technology is a noise-cancelling headphone device, including a speaker unit 4 provided with a dome-shaped diaphragm 2 having a center dome 5 and a sub-dome 6, a microphone 31 that detects ambient noise incident into the speaker unit, a baffle plate 17 supporting the speaker unit and provided with sound emission holes 20, 22 to radiate reproduction sound emitted from the speaker unit, and a signal processing circuit to generate noise cancellation signal generated based on the ambient noise detected by the microphone, wherein an acoustic resistance member 35 is provided at the position facing the sub-dome 6 of the dome diaphragm.

The present disclosure relates to a geranylgeranyl pyrophosphate synthase variant; a polynucleotide encoding the variant; a vector including the polynucleotide; a microorganism including any one or more of the variant, the polynucleotide, and the vector; a method of producing tetraterpene, a precursor thereof, or a material having tetraterpene as a precursor using the same; a composition for producing tetraterpene, a precursor thereof, or a material having tetraterpene as a precursor; and use of the microorganism including any one or more of the variant, the polynucleotide, and the vector, for producing tetraterpene, a precursor thereof, and a material having tetraterpene as a precursor.

The present application belongs to the technical field of board card detection and aging management, and particularly relates to a universal board card automatic detection device. An upper computer formulates a board card test procedure, generates a control instruction, controls other units to work in coordination to complete function test, simulation test and dynamic impedance test of the board card, and gives a test report and various statistical results; a power supply provides various input signal power or power supply according to the upper computer instruction. V&I curve and impedance test of digital IC components are completed through a clamp. V&I curve and impedance test of analog components are completed through a probe. Frequency, voltage and current function test of components are completed through a probe. The present application can select appropriate test items according to the characteristics of the board card, the requirements of regulations and actual needs, and the test items can be combined autonomously.

The present disclosure relates to a use of (R)-4-{(R)-1-[7-(3,4,5-trimethoxyphenyl)-[1,6] naphthyridin-5-yloxy]-ethyl}pyrrolidin-2-one in treating kidney disease. According to the present disclosure, (R)-4-{(R)-1-[7-(3,4,5-trimethoxy-phenyl)-[1,6] naphthyridin-5-yloxy]-ethyl}pyrrolidin-2-one of the present disclosure palliates clinical symptoms and alleviates renal failure and renal injury through reduction of blood glucose levels and insulin resistance in diabetic nephrosis animal models. Thus, the compound may be advantageously applied to a use for preventing or treating kidney diseases, especially diabetic renal diseases.

The present invention provides a cannabidiol derivative, a method for preparing same, and a composition for cognitive function improvement comprising same. The novel cannabidiol derivative of the present invention has been confirmed to exhibit acetylcholinesterase inhibitory activity and butyrylcholinesterase inhibitory activity, as well as inhibitory activity against monoamine oxidase B. Therefore, it is possible to simultaneously treat a decrease in acetylcholine levels in brain tissue and a decrease in blood butyrylcholine levels, which are seen in patients with dementia, and to provide a more effective cognitive function improvement treatment by preventing brain cell damage. Therefore, the cannabidiol derivative, the method for preparing same, and the composition for improving cognitive function comprising same, of the present invention, can be usefully used as a substance for improving cognitive function in the field of medicine and dietary supplement that can simultaneously inhibit acetylcholinesterase, butyrylcholinesterase, and monoamine oxidase B.

A clamp device suitable for large-specification disc isothermal forgings comprises two clamp seats which are oppositely arranged, the front side faces of the two clamp seats are each provided with a U-shaped jaw groove with an opening, the two U-shaped jaw grooves are oppositely arranged, the two sides of each U-shaped jaw groove are each provided with a clamp foot, and the clamp feet are arranged on the two sides of each U-shaped jaw groove. An arc-shaped jaw groove with an opening is formed in the upper surface of each clamp seat, and the two arc-shaped jaw grooves are oppositely arranged. According to the clamp device, large-diameter blanks can be clamped through the arc-shaped jaw grooves, the transverse slippage phenomenon is reduced, large-specification disc forgings can be longitudinally supported through the U-shaped jaw grooves, the probability of slippage in the vertical direction is remarkably reduced, the clamping efficiency is improved, a mold and the forgings can be conveniently separated, forgings can be conveniently demolded, and the mechanical arm clamp function is improved; the requirement for the level of a manipulator operator can be relatively lowered, human factors in the technological production process are reduced, and the production efficiency is improved.

The invention features polypeptides that include an extracellular ActRlla variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRlla variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, e.g., Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; or metabolic diseases, e.g., obesity, Type-1 diabetes, or Type-2 diabetes.